Sorafenib Bluefish: Uses, Dosage & Side Effects
Multi-Kinase Inhibitor — Blocks tumor growth and angiogenesis in advanced liver, kidney, and thyroid cancer
Quick Facts About Sorafenib Bluefish
Key Takeaways About Sorafenib Bluefish
- Treats three cancers: Sorafenib is approved for advanced hepatocellular carcinoma (HCC, liver cancer), advanced renal cell carcinoma (RCC, kidney cancer), and radioiodine-refractory differentiated thyroid cancer (DTC) in adults
- Dual mechanism: Simultaneously blocks tumor cell growth (through the RAF/MEK/ERK pathway) and tumor blood vessel formation (through VEGFR-2 and VEGFR-3), making it a cornerstone of targeted antiangiogenic therapy
- Standard dose is 400 mg twice daily: Two 200 mg tablets taken twice daily (800 mg total per day), on an empty stomach or with a low- to moderate-fat meal; avoid high-fat meals as they reduce absorption by 30%
- Hand-foot skin reaction is common: Painful redness, swelling, and blistering on palms and soles affects many patients; prevention with urea-based emollients, padded shoes, and early dose modification is essential
- Blood pressure and wound healing: Monitor blood pressure weekly during the first 6 weeks; stop sorafenib at least 10 days before major surgery due to impaired wound healing and increased bleeding risk
What Is Sorafenib Bluefish and What Is It Used For?
Sorafenib Bluefish contains sorafenib, an orally active multi-kinase inhibitor that simultaneously blocks several enzymes involved in tumor cell proliferation and tumor blood vessel formation (angiogenesis). By inhibiting kinases such as RAF, BRAF, VEGFR-2, VEGFR-3, PDGFR-beta, KIT, and FLT-3, sorafenib slows cancer growth and spread in advanced hepatocellular carcinoma, renal cell carcinoma, and radioiodine-refractory differentiated thyroid cancer.
Sorafenib Bluefish is a prescription-only targeted therapy used in specialist oncology care for adults with three types of advanced cancer. It belongs to a class of medications called tyrosine kinase inhibitors (TKIs), and more specifically multi-kinase inhibitors, because it blocks multiple intracellular and membrane-bound kinases simultaneously. Sorafenib was one of the first oral targeted cancer therapies to demonstrate a clear survival benefit in advanced liver cancer, a malignancy that had very limited treatment options before its approval in 2007.
Solid tumors depend on two fundamental processes to grow and spread: the rapid proliferation of cancer cells themselves, and the formation of new blood vessels to supply those cells with oxygen and nutrients (a process called angiogenesis). Sorafenib was designed to interrupt both processes at the same time. On the tumor cell, it inhibits the RAF/MEK/ERK signaling pathway, a crucial driver of uncontrolled cell division in many solid tumors. On the vascular endothelium, it blocks VEGFR-2 and VEGFR-3, receptors that normally promote the sprouting of new capillaries feeding the cancer. The result is a dual hit that slows both tumor growth and tumor vascularization.
Unlike chemotherapy, which kills rapidly dividing cells indiscriminately and causes widespread toxicity, sorafenib is a targeted therapy that acts on specific molecular pathways. This does not make it free of side effects — in fact, class-specific effects such as hand-foot skin reaction, hypertension, and diarrhea are common — but the toxicity profile differs substantially from classical cytotoxic drugs and allows long-term oral outpatient use.
Sorafenib Bluefish is a generic formulation of sorafenib authorized as bioequivalent to the originator product Nexavar, developed by Bayer and Onyx Pharmaceuticals. Generic medicines must demonstrate identical quality, strength, purity, and bioavailability as the reference product and are approved by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and other regulatory agencies worldwide under strict bioequivalence standards.
Approved Indications
Sorafenib Bluefish is approved for the treatment of three specific advanced cancers in adult patients:
- Hepatocellular carcinoma (HCC): The treatment of hepatocellular carcinoma (the most common form of primary liver cancer) in adults with preserved liver function (Child-Pugh A) when surgery, liver transplantation, or locoregional therapies such as transarterial chemoembolization (TACE) are not suitable or have failed. Sorafenib was the first systemic therapy to improve overall survival in advanced HCC, based on the SHARP trial.
- Advanced renal cell carcinoma (RCC): The treatment of advanced renal cell carcinoma (kidney cancer) in adults who have failed prior interferon-alpha or interleukin-2-based therapy, or for whom such therapy is considered unsuitable. Its approval was supported by the pivotal TARGET trial.
- Differentiated thyroid carcinoma (DTC): The treatment of progressive, locally advanced, or metastatic differentiated thyroid carcinoma (papillary, follicular, or Hürthle cell) that is refractory to radioactive iodine (RAI-refractory DTC) in adults. Approval was based on the DECISION trial.
Sorafenib is an oral multi-kinase inhibitor with a dual mechanism of action. Intracellularly, it inhibits the serine/threonine kinases CRAF, BRAF, and the oncogenic mutant BRAF V600E, thereby suppressing the RAF/MEK/ERK signaling cascade that drives tumor cell proliferation and survival. On the cell surface, it inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and progression, including vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-beta), KIT, FLT-3, and RET. This broad inhibition interrupts both tumor cell division and the formation of new blood vessels that feed the tumor, leading to reduced tumor growth and delayed disease progression. The multi-targeted mechanism also explains both the antitumor activity across different malignancies and the characteristic toxicity profile (hand-foot skin reaction, hypertension, diarrhea).
Where Sorafenib Sits in Treatment Algorithms
Sorafenib was the first systemic therapy approved for advanced hepatocellular carcinoma and, for more than a decade, remained the standard of care in the first-line setting. International guidelines (ESMO, EASL, AASLD) continue to list sorafenib as a proven first-line option for patients with advanced HCC and preserved liver function, alongside newer alternatives such as lenvatinib and immune checkpoint inhibitor combinations (atezolizumab plus bevacizumab). In kidney cancer, sorafenib is now most commonly used in later lines of therapy after progression on other targeted agents or immune checkpoint inhibitors. In radioiodine-refractory differentiated thyroid cancer, sorafenib and lenvatinib are the two oral multi-kinase inhibitors specifically approved, and the choice between them is guided by patient-specific factors, comorbidities, and the side effect profile a patient can best tolerate.
Who Prescribes Sorafenib Bluefish
Sorafenib Bluefish is a specialist oncology medicine and must be prescribed and monitored by physicians experienced in the treatment of cancer patients, such as medical oncologists, hepatologists with oncology expertise, or endocrine oncologists for thyroid cancer. Treatment requires frequent blood tests, regular imaging to assess tumor response, blood pressure monitoring, dermatology input for hand-foot skin reaction, and a multidisciplinary team approach. Self-initiation of sorafenib is not possible, and dose decisions should always be made by the treating oncology team.
What Should You Know Before Taking Sorafenib Bluefish?
Before starting sorafenib, your oncologist will assess your liver function, blood pressure, cardiovascular status, thyroid function, and any bleeding risk. Sorafenib is contraindicated in patients with hypersensitivity to sorafenib and in pregnant women. Special caution is needed if you have uncontrolled hypertension, recent bleeding, unhealed wounds, or planned surgery within the next 10 days.
Sorafenib is a powerful targeted therapy that affects multiple organ systems beyond the tumor itself. A thorough pretreatment evaluation is essential to identify patients at higher risk of complications and to establish baseline values against which treatment-related changes can be tracked. Understanding the contraindications, warnings, and precautions helps you actively participate in your own safety during therapy.
Contraindications
You must not take Sorafenib Bluefish if any of the following apply:
- Hypersensitivity: If you have a known hypersensitivity (allergy) to sorafenib, to sorafenib tosylate, or to any of the tablet excipients, including lactose, croscarmellose sodium, sodium lauryl sulfate, or the film-coating components.
- Pregnancy: Sorafenib is contraindicated during pregnancy because of demonstrated teratogenic and embryotoxic effects in animal studies. Women of childbearing potential must use highly effective contraception during treatment and for at least 2 weeks after the final dose.
- Combined with carboplatin and paclitaxel in squamous cell lung cancer: Clinical trial data showed an increased risk of death in patients with squamous cell lung cancer when sorafenib was added to carboplatin plus paclitaxel. This combination must not be used.
Warnings and Precautions
Discuss the following conditions with your oncologist before starting Sorafenib Bluefish. They may require baseline testing, prophylactic measures, modified dosing, or alternative treatment approaches:
- Severe or sudden chest pain, shortness of breath, or signs of a heart attack
- Unexplained bleeding (coughing up blood, vomiting blood, black or bloody stools, severe nosebleeds, heavy vaginal bleeding, or a severe headache suggesting brain bleed)
- Severe skin reactions with blistering, peeling, or mucous membrane involvement (possible Stevens-Johnson syndrome or toxic epidermal necrolysis)
- Very high blood pressure with headache, visual disturbance, confusion, or seizure (possible hypertensive crisis or posterior reversible encephalopathy syndrome)
- Severe abdominal pain, which could indicate bowel perforation
- Yellow skin or eyes, dark urine, or right upper abdominal pain (possible severe liver injury)
- Hand-foot skin reaction and dermatologic toxicity: Painful redness, swelling, calluses, or blisters on the palms of the hands and soles of the feet (palmar-plantar erythrodysesthesia) are very common. Most cases appear within the first 6 weeks. Severe forms may require dose reduction or interruption. Rarely, more serious reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome have occurred.
- Hypertension: Sorafenib frequently causes a rise in blood pressure, typically early in treatment. Blood pressure should be monitored weekly during the first 6 weeks and regularly thereafter. Hypertension is managed according to general cardiovascular guidelines; severe or uncontrolled hypertension may require dose interruption.
- Bleeding: All VEGF-pathway inhibitors, including sorafenib, can increase the risk of bleeding. Patients with active peptic ulcers, known varices, recent hemoptysis, or anticoagulant therapy require careful evaluation. Dose interruption is usually necessary for significant bleeding events.
- Cardiac ischemia and heart failure: Myocardial ischemia and infarction, as well as cardiac failure, have been reported. Patients with prior coronary artery disease should be monitored closely, and treatment should be interrupted in those who develop cardiac ischemia.
- QT-interval prolongation: Sorafenib can prolong the QT interval on the electrocardiogram. Electrolyte disturbances (especially low potassium, magnesium, or calcium) should be corrected before starting treatment, and caution is needed in patients with congenital long QT syndrome or those taking other QT-prolonging drugs.
- Gastrointestinal perforation: Although uncommon, perforation of the stomach or intestine has been reported. Severe abdominal pain, persistent vomiting, or inability to tolerate oral intake should prompt immediate medical evaluation.
- Impaired wound healing: Sorafenib interferes with the formation of new blood vessels needed for wound repair. Discontinue sorafenib at least 10 days before any planned major surgery, and do not resume until full wound healing has been achieved.
- Hepatitis and liver toxicity: Drug-induced hepatitis, with elevations in transaminases, bilirubin, or prothrombin time, has been reported and in rare cases has led to liver failure. Liver function must be monitored throughout treatment, especially in patients with underlying liver disease.
- Thyroid dysfunction: Sorafenib can cause thyroid dysfunction, most often hypothyroidism but occasionally hyperthyroidism. TSH should be checked at baseline and monitored periodically. Thyroid hormone replacement is given as needed.
- Osteonecrosis of the jaw (ONJ): Rare cases of ONJ have been described, particularly in patients with prior or concomitant bisphosphonate exposure or recent invasive dental procedures. A dental examination before starting treatment is recommended in patients at risk.
Blood Test and Monitoring Schedule
Sorafenib can affect the liver, kidneys, thyroid, and electrolyte balance, often before symptoms appear. Your oncology team will arrange regular monitoring that typically includes:
- Complete blood count: at baseline and periodically
- Liver function tests (ALT, AST, bilirubin, alkaline phosphatase): at baseline and regularly during treatment, especially in liver cancer patients
- Kidney function (creatinine, urea) and electrolytes (potassium, magnesium, calcium): at baseline and periodically
- Lipase and amylase: periodically, due to the risk of pancreatic enzyme elevation
- Thyroid-stimulating hormone (TSH): at baseline and every 2 to 3 months during treatment
- Blood pressure: weekly during the first 6 weeks, then at every clinic visit
- Urinalysis for proteinuria: periodically
- Imaging (CT or MRI) and tumor markers (AFP in HCC, thyroglobulin in DTC): at regular intervals to assess response
Pregnancy, Breastfeeding, and Fertility
Sorafenib Bluefish can harm a developing fetus. Observational and non-clinical data demonstrate teratogenic and embryotoxic effects, and the drug must not be used during pregnancy unless the clinical condition of the woman absolutely requires treatment with sorafenib. Key precautions include:
- Women of childbearing potential must use a highly effective method of contraception during treatment and for at least 2 weeks after the final dose of sorafenib.
- Men (including those who have had a vasectomy) with a partner who is pregnant or of childbearing potential should use a condom during treatment and for at least 2 weeks after the final dose to protect their partner from exposure through seminal fluid.
- Breastfeeding is not recommended during sorafenib treatment and for at least 2 weeks after the final dose, as it is unknown whether sorafenib is excreted in breast milk, and there is potential risk to the infant.
- Both men and women treated with sorafenib should discuss fertility preservation options (such as sperm or egg banking) with their oncologist prior to treatment if future fertility is a concern, as sorafenib may impair fertility.
Driving and Operating Machinery
There are no specific studies on the effects of sorafenib on the ability to drive or operate machinery. However, fatigue is a very common side effect, and some patients may experience dizziness. If you feel tired, dizzy, or unwell, you should avoid driving or operating potentially dangerous machinery until the symptoms have resolved.
Important Information About Excipients
Sorafenib Bluefish 200 mg film-coated tablets contain excipients that are worth noting for certain patients. They typically include sodium lauryl sulfate and a small amount of sodium. Patients following a strict low-sodium diet should take this into account. If you have been told by your doctor that you are intolerant to certain other inactive ingredients, review the full package leaflet provided with your medicine and discuss any concerns with your pharmacist.
How Does Sorafenib Bluefish Interact with Other Drugs?
Sorafenib interacts with drugs that affect CYP3A4 (the main enzyme that metabolizes it) and UGT1A1/1A9 (glucuronidation pathways). Strong CYP3A4 inducers such as rifampicin, phenytoin, and St. John's Wort can significantly reduce sorafenib levels and efficacy. Sorafenib also increases levels of drugs such as warfarin, docetaxel, doxorubicin, and irinotecan, and can cause additive QT prolongation with other QT-prolonging medicines.
Drug interactions with sorafenib occur through several mechanisms. Sorafenib is primarily metabolized by the hepatic enzyme CYP3A4 (by oxidation) and UGT1A9 (by glucuronidation). Drugs that strongly induce or inhibit these pathways can significantly alter sorafenib exposure. Sorafenib itself is a moderate inhibitor of UGT1A1 and UGT1A9 and weakly inhibits several CYP enzymes, which affects the metabolism of some co-administered drugs. In addition, sorafenib can increase the international normalized ratio (INR) in patients taking warfarin and contribute to additive QT prolongation with other QT-prolonging drugs.
Always inform your oncologist and pharmacist about all medications you are taking, including over-the-counter drugs, dietary supplements, and herbal remedies, before starting and throughout sorafenib treatment. Do not start any new medication, supplement, or herbal product without first checking with your oncology team.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments, alternative medications, or additional monitoring:
| Drug / Class | Interaction Mechanism | Clinical Action |
|---|---|---|
| Rifampicin, phenytoin, carbamazepine, phenobarbital | Strong CYP3A4 inducers that reduce sorafenib blood levels by up to 30–40% | Avoid if possible; if essential, consider alternative and monitor clinical response |
| St. John's Wort (Hypericum perforatum) | Herbal CYP3A4 inducer that can significantly lower sorafenib levels | Avoid concurrent use — may reduce antitumor efficacy |
| Warfarin and other oral anticoagulants | Rare but clinically important bleeding events and increased INR | Monitor INR more frequently; watch for bleeding |
| Docetaxel | Sorafenib increases docetaxel AUC by 36–80%, risk of added toxicity | Combination not generally recommended outside clinical trials |
| Doxorubicin | Sorafenib increases doxorubicin exposure by around 20% | Use with caution; monitor for enhanced cardiotoxicity and myelosuppression |
| Irinotecan | Sorafenib inhibits UGT1A1, increasing SN-38 (active irinotecan metabolite) levels | Avoid or reduce irinotecan dose; monitor for severe diarrhea and neutropenia |
| Carboplatin + paclitaxel in squamous NSCLC | Increased mortality observed in clinical trial | Contraindicated in patients with squamous cell lung cancer |
| Neomycin and other oral antibiotics | Disrupt enterohepatic recirculation, reducing sorafenib AUC by ~50% | Avoid prolonged concurrent use where possible |
| QT-prolonging drugs (amiodarone, sotalol, methadone, some fluoroquinolones, ondansetron, haloperidol) | Additive QT-interval prolongation; risk of torsade de pointes | Correct electrolytes; baseline and periodic ECG; use alternatives if possible |
Other Notable Interactions
A number of additional medicines can interact with sorafenib in clinically relevant ways. The following table highlights some of the more frequently encountered interactions in everyday oncology practice:
| Drug | Effect | Action Required |
|---|---|---|
| Dexamethasone | Moderate CYP3A4 induction may lower sorafenib levels | Use with caution; monitor clinical response |
| Midazolam, dextromethorphan (CYP3A4/CYP2D6 substrates) | No clinically significant change shown in studies | No routine dose adjustment required |
| Paclitaxel | Variable pharmacokinetic changes with sorafenib | Use of combination should be guided by specialist oncology protocols |
| Capecitabine | Sorafenib may increase 5-FU plasma levels when co-administered | Monitor for enhanced hand-foot syndrome, diarrhea, and stomatitis |
| Grapefruit and grapefruit juice | CYP3A4 inhibition in the gut wall — theoretical increase in sorafenib levels | Generally avoid grapefruit and grapefruit juice during treatment |
| Digoxin | Potential for sorafenib to alter digoxin absorption via transporter effects | Monitor digoxin levels if used concurrently |
Sorafenib absorption is reduced by approximately 30% when taken with a high-fat meal compared with fasting. To ensure consistent blood levels, Sorafenib Bluefish should be taken without food (at least 1 hour before or 2 hours after a meal) or with a low- to moderate-fat meal. Grapefruit and grapefruit juice should be avoided because they inhibit CYP3A4 in the intestinal wall and may unpredictably alter sorafenib exposure.
What Is the Correct Dosage of Sorafenib Bluefish?
The recommended adult dose is 400 mg (two 200 mg tablets) taken twice daily, morning and evening, giving a total daily dose of 800 mg. Tablets should be swallowed whole with a glass of water, without food or with a low- to moderate-fat meal. Dose reductions to 400 mg once daily or 400 mg every other day may be required to manage side effects.
Sorafenib Bluefish is prescribed exclusively by physicians experienced in the management of advanced cancer. The standard dose is the same across all three approved indications (hepatocellular carcinoma, renal cell carcinoma, and radioiodine-refractory differentiated thyroid cancer). Strict adherence to the dosing schedule is important for both efficacy and the early detection of side effects.
Adults
| Component | Dose | Instructions |
|---|---|---|
| Standard dose (HCC, RCC, DTC) | 400 mg (2 × 200 mg tablets) twice daily | Total 800 mg/day, morning and evening; without food or with low/moderate-fat meal |
| First dose reduction | 400 mg (2 × 200 mg) once daily | For grade 2 persistent or grade 3 toxicity; reintroduce full dose if tolerated |
| Second dose reduction | 400 mg every other day | For recurrent or higher-grade toxicity after first reduction |
| Treatment interruption | Temporary hold | For grade 4 toxicity, severe skin reaction, hypertensive crisis, or planned surgery |
How to Take Sorafenib Bluefish
Careful adherence to the following instructions is essential for safe and effective treatment:
- Timing of food: Take the tablets either on an empty stomach (at least 1 hour before or 2 hours after a meal) or together with a low- or moderate-fat meal. A high-fat meal reduces absorption by around 30%.
- Swallow whole: Swallow the tablets whole with a glass of water. Do not crush, split, or chew the tablets.
- Twice daily, around the same times: Take one morning dose and one evening dose approximately 12 hours apart to keep blood levels as stable as possible.
- Consistent routine: Try to take sorafenib at the same two times each day. Set an alarm or use a pill organizer if helpful.
- Contact the team before stopping: Do not change or stop your dose unless your oncology team tells you to, even if you feel well — sorafenib is often taken long-term.
Children and Adolescents
The safety and efficacy of sorafenib in children and adolescents younger than 18 years have not been established in the approved indications. There are no approved pediatric indications for sorafenib in hepatocellular carcinoma, renal cell carcinoma, or differentiated thyroid carcinoma. Any use in children or adolescents is considered off-label and should only occur in specialized pediatric oncology centers, ideally within the context of a clinical trial.
Elderly Patients
No specific dose adjustment based on age alone is required. Clinical trials included substantial proportions of patients aged 65 years and older. However, elderly patients may have reduced organ reserve and more comorbidities and may therefore be more susceptible to certain side effects, particularly hypertension, cardiovascular events, and hand-foot skin reaction. Close clinical monitoring, prompt dose adjustments, and careful supportive care help optimize tolerability in older patients.
Patients with Liver Impairment
Many patients receiving sorafenib for hepatocellular carcinoma have some degree of underlying liver dysfunction. Dosing recommendations are based on Child-Pugh classification:
Hepatic Impairment Dosing
- Mild impairment (Child-Pugh Class A): No dose adjustment recommended. Most HCC trials enrolled patients in this category.
- Moderate impairment (Child-Pugh Class B): Sorafenib can be used with close monitoring; some clinicians start at a reduced dose. Liver function, bilirubin, and coagulation should be followed closely.
- Severe impairment (Child-Pugh Class C): Sorafenib is not recommended, as the risk of worsening liver function and serious adverse events outweighs the expected benefit.
Treatment should be interrupted if bilirubin doubles or if transaminases rise to more than 20 times the upper limit of normal. Resumption at a lower dose may be considered once values normalize.
Patients with Kidney Impairment
No dose adjustment is required in patients with mild to severe renal impairment who are not on dialysis. Sorafenib is primarily eliminated through the hepatobiliary route, with only a small fraction excreted unchanged by the kidneys. Data in patients requiring dialysis are limited, so such patients should be monitored particularly closely. Patients with proteinuria detected on urinalysis should have the severity and progression reviewed; significant or nephrotic-range proteinuria may require dose interruption.
Missed Dose
If you miss a dose of Sorafenib Bluefish, take it as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. If you vomit shortly after taking a dose and cannot tell how much was absorbed, do not take an extra dose; wait until the next scheduled time and contact your oncology team if vomiting persists.
Overdose
If more Sorafenib Bluefish has been taken than prescribed, contact your oncologist or a poison control center immediately, or go to the nearest hospital emergency department. There is no specific antidote for sorafenib overdose. Management is symptomatic and supportive, with particular attention to blood pressure, hydration, skin and mucosal integrity, gastrointestinal symptoms, and cardiac monitoring. Doses up to 800 mg twice daily have been tested in studies and typically cause dose-limiting diarrhea and skin toxicity.
Do not stop taking Sorafenib Bluefish without discussing it with your oncologist, even if you feel well. Stopping the medicine without medical guidance may allow your cancer to progress more rapidly. Many side effects are manageable with dose modifications and supportive care; your oncology team can help you decide whether continuing at a lower dose, interrupting briefly, or switching to a different therapy is the best option.
What Are the Side Effects of Sorafenib Bluefish?
Like all targeted therapies, sorafenib causes predictable class-specific side effects. The most common are hand-foot skin reaction, diarrhea, fatigue, rash, hair loss, high blood pressure, nausea, weight loss, and bleeding tendencies. Serious but rarer events include myocardial infarction, gastrointestinal perforation, severe skin reactions, and hepatitis. Most effects are dose-dependent and manageable with dose modification and supportive care.
The side effect profile of sorafenib reflects its mechanism of action. Inhibition of VEGFR pathways explains hypertension, bleeding, impaired wound healing, and proteinuria. Inhibition of kinases in rapidly dividing epithelial tissues explains hand-foot skin reaction, rash, stomatitis, and alopecia. RAF/MEK/ERK inhibition contributes to fatigue, skin changes, and diarrhea. Awareness of these expected effects enables early recognition, proactive supportive care, and appropriate dose modifications — all of which help keep patients on effective therapy for as long as possible.
- Severe chest pain, pressure, tightness, or shortness of breath — possible heart attack or heart failure
- Sudden weakness on one side of the body, slurred speech, severe headache, or confusion — possible stroke or PRES
- Vomiting blood, coughing up blood, or passing black or bloody stools — possible serious bleeding
- Severe or widespread skin blistering, peeling of the skin, or mucous membrane involvement — possible SJS/TEN
- Severe abdominal pain with fever and vomiting — possible gastrointestinal perforation
- Yellowing of the skin or eyes, dark urine, or severe right upper abdominal pain — possible liver failure
Very Common Side Effects
- Hand-foot skin reaction (palmar-plantar erythrodysesthesia)
- Diarrhea
- Rash
- Fatigue, weakness (asthenia)
- Hair loss (alopecia)
- High blood pressure (hypertension)
- Nausea and vomiting
- Weight loss and decreased appetite
- Abdominal pain
- Bleeding events (most commonly nosebleeds)
- Elevated lipase and amylase levels
- Reduced phosphate levels in the blood (hypophosphatemia)
- Itchy skin (pruritus)
- Dry skin
- Mouth inflammation (stomatitis)
Common Side Effects
- Low red blood cell count (anemia)
- Low white blood cell or platelet counts
- Hypothyroidism (including in thyroid cancer patients)
- Low sodium (hyponatremia)
- Depression
- Headache, tingling or numbness (sensory neuropathy)
- Tinnitus
- Heart failure
- Heart attack (myocardial infarction), myocardial ischemia
- Hoarseness (dysphonia)
- Reflux (GERD)
- Constipation
- Increased liver enzymes
- Muscle and joint pain, muscle spasms
- Kidney problems with protein in the urine (proteinuria)
- Erectile dysfunction
- Fever
- Increased INR or bleeding in patients on anticoagulants
Uncommon Side Effects
- Allergic reactions, including skin reactions and urticaria
- Dehydration
- Hyperthyroidism
- Hypertensive crisis
- Rhinorrhea, interstitial lung disease-like events
- Pancreatitis, gastritis, gastrointestinal perforation
- Jaundice, drug-induced hepatitis, cholecystitis
- Eczema, multiform erythema
- Gynecomastia (breast enlargement in men)
- Worsening of existing kidney disease
- Hypomagnesemia
- QT-interval prolongation on ECG
Rare Side Effects
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Anaphylactic reaction
- Posterior reversible encephalopathy syndrome (PRES)
- Radiation-recall dermatitis
- Osteonecrosis of the jaw
- Severe liver injury with hepatic failure
- Nephrotic syndrome
Frequency Not Known
- Secondary malignancies (e.g., keratoacanthoma, cutaneous squamous cell carcinoma)
- Aortic aneurysm and aortic dissection (class effect of VEGF-pathway inhibitors)
- Thrombotic microangiopathy
- Rhabdomyolysis
- Encephalopathy (non-PRES)
Managing Hand-Foot Skin Reaction
Hand-foot skin reaction (HFSR) is the most recognizable and often the most bothersome side effect of sorafenib. Symptoms begin with tingling, numbness, or mild redness on the palms and soles within the first 2 to 4 weeks of treatment and may progress to thick calluses, painful blisters, and peeling. Practical measures can significantly reduce severity:
- Before starting treatment, a pedicure to remove existing calluses and hyperkeratotic areas on the feet
- Wearing comfortable, well-cushioned, soft shoes with gel insoles and cotton socks
- Avoiding activities that cause friction or pressure on the hands and feet (heavy gardening, long walks, tight gloves)
- Avoiding hot water (hot baths, long showers, dishwashing)
- Liberal use of thick emollients containing 10–20% urea or similar keratolytics twice daily
- Topical corticosteroids for inflamed areas, as directed by a dermatologist
- Prompt reporting of painful blisters or difficulty walking; dose reduction or short interruption is often required for grade 2 or higher HFSR
Managing Hypertension
Sorafenib-induced hypertension is a pharmacologic class effect of VEGF-pathway inhibition. It is most common during the first 6 weeks. Regular home blood pressure monitoring is ideal. Standard antihypertensive agents (ACE inhibitors, angiotensin receptor blockers, calcium channel blockers) are generally effective; diuretics are used with caution because of the risk of electrolyte disturbance. Severe or resistant hypertension may require dose reduction or temporary discontinuation of sorafenib.
Managing Diarrhea, Fatigue, and Nutritional Issues
Diarrhea affects a majority of patients on sorafenib. Early intervention with loperamide at the first loose stool, adequate hydration with electrolyte-containing fluids, avoiding high-fiber and high-lactose foods during flares, and eating small, frequent meals can all help. Fatigue is managed with gentle physical activity, sleep hygiene, management of anemia if present, and attention to thyroid function. Weight loss and muscle loss should prompt dietary counseling and, when appropriate, referral to a clinical nutritionist. Unintentional weight loss is an independent prognostic factor and should not be ignored.
If you experience any side effects, including those not listed above, report them to your oncologist or healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting side effects helps ensure the continued safety monitoring of medications for all patients.
How Should You Store Sorafenib Bluefish?
Store Sorafenib Bluefish in its original packaging at normal room temperature (below 25°C), out of the reach and sight of children. No special refrigeration is required. Do not use after the expiration date printed on the carton or blister pack. Return unused tablets to a pharmacy for safe disposal.
Correct storage keeps the medicine stable and effective throughout its shelf life. Sorafenib film-coated tablets are relatively resistant to normal household temperature variations but should still be protected from moisture, heat, and light.
- Temperature: Store at normal room temperature, typically below 25°C (77°F). Do not refrigerate or freeze.
- Packaging: Keep the tablets in the original blister packs inside the carton to protect them from humidity and light. Do not repackage into pillboxes for long periods.
- Children: Keep well out of the sight and reach of children. Accidental ingestion of sorafenib by a child is a medical emergency requiring immediate evaluation at a hospital.
- Expiration: Do not use sorafenib tablets after the expiration date (marked “EXP”) printed on the blister and carton. The expiration date refers to the last day of the indicated month.
- Disposal: Do not dispose of medicines in wastewater or household waste. As a cytotoxic medicine, return any unused tablets to a pharmacy for safe, environmentally appropriate disposal, in line with local regulations.
- Handling: Caregivers, especially those who are pregnant or may become pregnant, should avoid unnecessary direct handling of the tablets and wash their hands after contact with the medication or with a patient's urine, stool, or vomit.
- Travel: When traveling, keep tablets in their original packaging, carry them in your hand luggage, and bring a copy of your prescription and a letter from your clinician. Avoid leaving the tablets in a hot car or in direct sunlight.
What Does Sorafenib Bluefish Contain?
Each Sorafenib Bluefish film-coated tablet contains 200 mg of sorafenib (as sorafenib tosylate) as the active ingredient, together with standard pharmaceutical excipients in the tablet core and film coating. The tablets are designed for oral administration and are bioequivalent to the originator product, Nexavar.
Understanding the composition of your medicine helps identify potential allergens or intolerances, and can be useful when discussing treatment with other healthcare providers, such as dentists, surgeons, or emergency physicians.
Active Ingredient
The active substance is sorafenib, present as sorafenib tosylate. Each film-coated tablet contains an amount of sorafenib tosylate equivalent to 200 mg of sorafenib free base. Sorafenib is a small-molecule inhibitor with the chemical formula C21H16ClF3N4O3 (molecular weight 464.83 g/mol for the free base). In the body, sorafenib is extensively bound to plasma proteins, metabolized primarily through the liver (by CYP3A4 oxidation and UGT1A9 glucuronidation), and eliminated mostly in the feces.
Excipients (Inactive Ingredients)
The typical inactive ingredients in Sorafenib Bluefish 200 mg film-coated tablets include:
- Tablet core: Microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, and magnesium stearate
- Film coating: Hypromellose, macrogol (polyethylene glycol), titanium dioxide, and red iron oxide (which gives the tablets their characteristic pink/red appearance)
Consult the specific package leaflet for the exact list of excipients for the batch you have received, as formulations can vary slightly between generic manufacturers.
Appearance and Pack Sizes
Sorafenib Bluefish 200 mg tablets are typically round or oval, red or pink film-coated tablets supplied in blister packs. Pack sizes may include 28, 56, 60, 100, or 112 tablets per carton, representing between one and two months of treatment at the standard dose. Not all pack sizes may be marketed in every country. The exact tablet markings, color, and pack size for your medicine are described in the package leaflet.
Marketing Authorization and Bioequivalence
Sorafenib Bluefish is manufactured and marketed by Bluefish Pharmaceuticals. Like all approved generic medicines, it has been authorized based on demonstrated bioequivalence to the originator product Nexavar (Bayer HealthCare). Bioequivalence means that Sorafenib Bluefish delivers the same active substance at the same rate and to the same extent as the originator, ensuring equivalent clinical efficacy and safety. Generic medicines must meet the same strict manufacturing, quality, and purity standards required by regulatory authorities such as the EMA, FDA, and WHO prequalification program.
Frequently Asked Questions About Sorafenib Bluefish
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). "Nexavar (sorafenib) — Summary of Product Characteristics (SmPC)." EMA Official European regulatory documentation for sorafenib and its generics.
- U.S. Food and Drug Administration (FDA). "NEXAVAR (sorafenib) — Prescribing Information." FDA FDA-approved labeling and safety information for sorafenib.
- Llovet JM, et al. (2008). "Sorafenib in Advanced Hepatocellular Carcinoma." New England Journal of Medicine. 359(4):378–390. doi:10.1056/NEJMoa0708857 Landmark SHARP trial demonstrating overall survival benefit of sorafenib in advanced HCC.
- Escudier B, et al. (2007). "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma." New England Journal of Medicine. 356(2):125–134. doi:10.1056/NEJMoa060655 TARGET trial demonstrating progression-free survival benefit in advanced RCC.
- Brose MS, et al. (2014). "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial." The Lancet. 384(9940):319–328. doi:10.1016/S0140-6736(14)60421-9 DECISION trial supporting approval of sorafenib in radioiodine-refractory DTC.
- Vogel A, et al. (2021). "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology. 32(6):801–805. doi:10.1016/j.annonc.2021.02.014 European Society for Medical Oncology guidelines positioning sorafenib in HCC therapy.
- Escudier B, et al. (2019). "Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology. 30(5):706–720. doi:10.1093/annonc/mdz056 ESMO guidelines for RCC management including tyrosine kinase inhibitor therapy.
- Filetti S, et al. (2022). "ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer." Annals of Oncology. 33(7):674–684. doi:10.1016/j.annonc.2022.04.009 Current ESMO guidance on sorafenib and other TKIs in advanced thyroid cancer.
- World Health Organization (WHO). "Model List of Essential Medicines." WHO Essential Medicines Reference list of priority medicines for primary and oncology care globally.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in oncology, pharmacology, and clinical medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Oncology Specialists
Licensed physicians specializing in medical oncology, hepatobiliary oncology, and endocrine oncology, with documented experience in targeted therapies and advanced cancer management.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of multi-kinase inhibitors, drug interactions, and evidence-based oncology prescribing.
Researchers
Academic researchers with peer-reviewed publications on tumor angiogenesis, kinase signaling, and clinical trials in hepatocellular, renal, and thyroid cancers.
Medical Review
Independent review panel that verifies all content against ESMO, NCCN, EASL, and current peer-reviewed research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, ESMO, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, pharmacology, internal medicine, and clinical research.